Research Paper Volume 16, Issue 11 pp 9569—9583
Attenuating bone loss in osteoporosis: the potential of corylin (CL) as a therapeutic agent
Figure 1. Inhibition of RANKL-induced osteoclast differentiation by CL. (A) Corylin structure chemically. (B) Cell viability of CL on BMMs at day 1, day 3, day 5, and day 7. (C) The TRAP staining image from BMMs treated with CL under osteoclast induction condition. (D, E) The number and area quantifying of mature osteoclast. The ns, not statistically significant; **P < 0.01; ***P < 0.001; ****P < 0.0001.